Trial · NCT07330596
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NCT07330596, Phase 2, Recruiting, Anhui Provincial Cancer Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC. Trials, record NCT07330596. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07330596
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
- NCT number
- NCT07330596
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 96 participants, estimated
- Lead sponsor
- Anhui Provincial Cancer Hospital
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- QL1706 combined with Chemotherapy, Chemotherapy
- First posted
- 2026-01-09
- Last updated
- 2026-01-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PFS | "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months" | Refers to the time from the start of medication to the first occurrence of disease progression or death from any cause |
| Secondary | ORR | through study completion, an average of 1 year | It refers to the proportion of patients whose tumor volume shrinks by 30% and can be maintained for more than four weeks, that is, the proportion of subjects who achieve complete response (CR) and partial response (PR) |
| Secondary | DCR | through study completion, an average of 1 year | It refers to the proportion of subjects who achieve complete remission (CR), partial remission (PR), and disease stability (SD) at the end of treatment |
| Secondary | DOR | through study completion, an average of 1 year | Refers to the time from the first judgment of complete remission (CR) or partial remission (PR) to the discovery of disease progression (PD) |
| Secondary | OS | through study completion, an average of 1 year | It refers to the time from the start of medication to death caused by any reason |
| Secondary | AE | through study completion, an average of 1 year | AE |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07330596
GET https://conductscience.org/api/trials/v1/NCT07330596/registered